Presently, Richard H. Douglas is Independent Chairman at MaxCyte, Inc. and Chairman for Aldeyra Therapeutics, Inc.

He is also on the board of Novavax, Inc., Intercell USA, Inc., Helio Vision, Inc. and Labyrinth Choir, Inc.

In his past career Dr. Douglas occupied the position of Senior Vice President-Corporate Development at Genzyme Corp. and Director-New Product Development at Integrated Genetics, Inc.

Richard H. Douglas received a doctorate from the University of California, Berkeley and an undergraduate degree from the University of Michigan.